arrow
R

Roberto Giugliani

hospital de clinicas de porto alegre
H指数:80
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The p.Ala1035Val variant in Niemann–Pick type C1: Clinical and molecular characterization in Brazilian and Portuguese patients suggests a shared founder effect

Niemann–Pick C1型病中的p.Ala1035Val变异:巴西和葡萄牙患者的临床及分子特征表明存在共同的奠基者效应

2026-04-010
PRE
Unveiling Mucopolysaccharidosis IIIC in Brazil: Diagnostic Journey and Clinical Features of Brazilian Patients Identified Through the MPS Brazil Network

揭示巴西黏多糖贮积症IIIC型:通过MPS Brazil网络识别的巴西患者的诊断历程与临床特征

2025-12-270
OAAI
Long-term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey

α-半乳糖苷酶A治疗法布里病成年患者的长期有效性与安全性结局:法布里结局登记研究20年数据

2025-11-060
OAAI
Clinical characteristics and real-world outcomes in patients with mucopolysaccharidosis II over 18 years: final report of the hunter outcome survey

黏多糖贮积症II型患者18年临床特征与真实世界结局:Hunter结局调查最终报告

2025-11-020
PRE
Venglustat in GM2 Gangliosidoses and Related Disorders: Results of the AMETHIST Randomized Controlled and Basket Trials

维格鲁斯塔特在GM2神经节苷脂贮积症及相关疾病中的应用:AMETHIST随机对照试验和篮式试验的结果

2025-10-150
OAAI
Comprehensive Characterization of a Cluster of Mucopolysaccharidosis IIIB in Ecuador

厄瓜多尔一例黏多糖贮积症IIIB簇的全面表征

2025-09-300
OAAI
Long-Term Safety and Clinical Outcomes With Olipudase Alfa Enzyme Replacement Therapy in Children and Adolescents With Acid Sphingomyelinase Deficiency

奥利普酶α酶替代治疗在酸鞘磷脂酶缺乏症儿童和青少年中的长期安全性与临床结局

2025-09-120
PREAI
Newborn Intravenous Injection of Liposomal CRISPR/Cas9 Complex Has No Incidence of Off-Targets or Tumors in Mice

新生小鼠经静脉注射脂质体CRISPR/Cas9复合物的实验中,未观察到脱靶效应或肿瘤发生。

2025-05-170
OA
Analysis of genomic ancestry and characterization of a new variant in MPS type VII
2025-04-250
OAAI